Efficacy and safety of low-molecular-weight collagen peptides in knee osteoarthritis: a randomized, double-blind, placebo-controlled trial
Frontiers in Nutrition · 04.09.2025 · 12
DOI: 10.3389/fnut.2025.1644899 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Nutrition, online erschienen am 04.09.2025. Verfasst von Sun-Young Park und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Korean Medicine, Pusan National University, Yangsan, Republic of Korea. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Knee osteoarthritis (OA) is a common degenerative joint disease with limited safe, long-term treatment options. Nutritional interventions, such as low-molecular-weight collagen peptides (LMCP), have emerged as promising non-pharmacological strategies for joint health. However, clinical evidence is insufficient. Therefore, we aimed to assess the efficacy and safety of LMCP supplementation in patients with knee OA.
Methods
In this double-blind, randomized, placebo-controlled trial, 80 adults aged 40–75 with Kellgren–Lawrence (KL) grade I or II OA received either 3,000 mg/day LMCP or a placebo for 180 days. Primary endpoint included changes in Western Ontario and McMaster Universities Osteoarthritis (WOMAC) pain scores. Secondary endpoints included visual analog scale (VAS), WOMAC physical function and total scores, joint space width (JSW), and inflammatory markers. Adverse events (AEs) and patient compliance were monitored throughout the study.
Results
LMCP supplementation significantly reduced WOMAC pain compared to the placebo (−1.90 ± 4.14 vs. 0.61 ± 3.97; p = 0.006). Improvements in WOMAC physical function and total scores were greater in the LMCP group than in the placebo group (−4.10 ± 9.64 vs. 0.71 ± 6.47, p = 0.035; −6.24 ± 14.69 vs. −0.45 ± 9.08; p = 0.028, respectively). No significant changes were observed in JSW or inflammatory markers. No AEs occurred.
Conclusions
Daily supplementation of 3,000 mg of LMCP for 180 days was safe and effective in relieving joint pain and improving function in patients with KL grade I or II knee OA. LMCP is a promising nutrition-based non-pharmacological therapeutic option, particularly for individuals seeking complementary options to long-term non-steroidal anti-inflammatory drug therapy. Clinical trial registration The trial was prospectively registered at the Clinical Research Information Service of South Korea (registration number: KCT0005507). The study was conducted at Pusan National University Korean Medicine Hospital ( https://cris.nih.go.kr/ ).
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Korean Medicine, Pusan National University, Yangsan, Republic of Korea.
- Department of Korean Medicine, The Graduate School, Pusan National University, Yangsan, Republic of Korea.
- Health Food Research and Development, NEWTREE Co., Ltd., Seoul, Republic of Korea.
- EVERSPRING Co., Ltd., Seongnam, Republic of Korea.
- Department of Korean Medicine Rehabilitation, Pusan National University Korean Medicine Hospital, Yangsan, Republic of Korea.
Zitieren
APA
Park, S. Y., Lee, S. H., Kim, H. T., Park, H. J., Kim, D. U., Kim, S. U., & Heo, I. (2025). Efficacy and safety of low-molecular-weight collagen peptides in knee osteoarthritis: a randomized, double-blind, placebo-controlled trial. Frontiers in Nutrition, 12. https://doi.org/10.3389/fnut.2025.1644899
Vancouver
Park SY, Lee SH, Kim HT, Park HJ, Kim DU, Kim SU, et al. Efficacy and safety of low-molecular-weight collagen peptides in knee osteoarthritis: a randomized, double-blind, placebo-controlled trial. Frontiers in Nutrition. 2025;12. doi:10.3389/fnut.2025.1644899
BibTeX
@article{Park2025,
author = {Park, Sun-Young and Lee, Sang-Hyun and Kim, Hyun Tae and Park, Hye-Jin and Kim, Do-Un and Kim, Seung Un and Heo, In},
title = {Efficacy and safety of low-molecular-weight collagen peptides in knee osteoarthritis: a randomized, double-blind, placebo-controlled trial},
journal = {Frontiers in Nutrition},
year = {2025},
volume = {12},
doi = {10.3389/fnut.2025.1644899}
}
EUVIMED